Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that chronic administration of finasteride in rats led to significant alterations in the epididymis and compromised sperm quality, effects that persisted even after 30 days of treatment cessation.

The study found that ezetimibe effectively reduced prostate enlargement in an animal model of benign prostatic hyperplasia, suggesting it as a potential alternative or complementary treatment.

This abstract reviews the unclear link between androgenic alopecia and prostate cancer, highlighting the need for further research to determine the mechanisms connecting these two conditions.

This study found that administering Finasteride for two weeks before surgery significantly reduced intraoperative blood loss in patients undergoing monopolar TURP, with the interventional group experiencing less mean blood loss and shorter operative times compared to the control group.

This study validated a highly selective and fast LC–MS/MS method for accurately measuring levels of tadalafil and finasteride in human plasma, adhering to international bioanalytical guidelines.

This article discusses the structure of the human type II 5 alpha-reductase gene and reports no new experimental results.

In a rat model, this study found that a hydrogel incorporating adipose-derived stem cells and nerve growth factor may aid in the recovery of erectile function following cavernous nerve injury.

This study observed that in hormone-starved prostate cancer cells, the androgen 5alpha-dihydrotestosterone rapidly induces matriptase activation and shedding, which involves androgen receptor signaling and requires both transcription and protein synthesis.

This study developed solid lipid nanoparticles for delivering a shRNA-encoding plasmid that effectively reduced 5α-reductase enzyme levels in vitro without significant cytotoxicity, suggesting potential therapeutic applications.

This review highlights recent advancements in prostate cancer treatments, particularly new drugs targeting signaling pathways and showing promise in clinical trials, but notes the high recurrence rate of castration-resistant cancer post-therapy, requiring ongoing efforts for effective solutions.

Testosterone boosts fluid and electrolyte secretion in seminal vesicles, aiding sperm function.

In this study, cyproterone acetate combined with estradiol dramatically improved hirsutism symptoms and significantly reduced plasma testosterone and androstenedione levels in patients over periods of up to three years.

This study found that combining finasteride and anastrozole was more effective in preventing and treating benign prostatic hyperplasia in rats than using either drug alone.

This article discusses the documented benefits of finasteride for managing benign prostatic hyperplasia, noting the need for monitoring due to its effects on serum PSA levels; it reports no adverse impact on prostate cancer detection.

This study found that finasteride treatment in adult hamsters led to significant testicular alterations and reduced spermatogenesis compared to untreated controls.

In this study, sequences upstream of the TGM3 gene were found to regulate epithelial-specific gene expression in keratinocytes, suggesting potential applications in gene therapy.

High doses of finasteride cause cell growth and tumors in mice.

This article discusses the FDA's decision not to approve 5α-reductase inhibitors for prostate cancer prevention, citing an increase in high-grade tumors but no mortality evidence, and reports no new results.

This article reviews the use of finasteride for treating benign prostatic hyperplasia and its chemopreventive potential for prostate cancer, but it calls for further discussion on its preventive use in high-risk groups.

This article summarizes various studies in adult urology, including those on diagnostic techniques for prostate cancer and outcomes of different treatments for benign prostatic hyperplasia, but reports no new findings.

This study found that dutasteride may reduce the likelihood of hospitalization for BPH-related surgery and newly detected prostate cancer, compared to finasteride, and suggests a budgetary benefit.

This study found that Thermobalancing therapy using Dr Allen's Device significantly improved symptoms and quality of life in men with benign prostatic hyperplasia, but larger prostate sizes may require longer treatment.

This case report highlights a rare occurrence of poorly differentiated endometrial carcinoma in a transgender man undergoing long-term testosterone therapy, underscoring the necessity of continued gynecologic care and further research into the effects of testosterone on endometrial health in this population.

In this study, researchers observed that Cuscuta reflexa extract mitigated inflammation and oxidative stress in testosterone-induced benign prostatic hypertrophy in Wistar rats, suggesting its potential as an adjunctive therapy for BPH.

This review discusses the prevalence and treatment of benign prostatic hyperplasia and reports no new findings; it emphasizes considering side effects and comorbidities in therapy choices.

In this review, extensive analysis using conditional mutant mice revealed that androgen and Wnt signals play crucial roles in the development and function of male external genitalia and erectile tissue, while also exploring various regulatory factors involved in their pathogenesis.

This study concluded that finasteride may safely reduce prostate size and improve urinary symptoms for at least six years in men with benign prostatic hyperplasia, though further improvements beyond six months are unlikely.

This study found that a new hybrid compound designed from finasteride and epristeride was a potent inhibitor of 5α-reductase with a mechanism similar to finasteride.

This study found that finasteride decreased plasma dihydrotestosterone levels and altered steroid metabolism, similar to the profile of male pseudohermaphrodites with inherited 5a-reductase deficiency.